Who is sponsoring NCT00077792?

NCT00077792 is sponsored by Sanofi.

What condition does NCT00077792 study?

NCT00077792 studies Myocardial Infarction, Acute ST-Segment Elevation.

What drugs are being tested in NCT00077792?

Interventions: Enoxaparin sodium (XRP4563).

What is the status of NCT00077792?

NCT00077792 is currently COMPLETED.

Last reviewed 2009-04-17 · How we verify

A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy

NCT00077792 Phase 3 COMPLETED

The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy

Details

Lead sponsor	Sanofi
Phase	Phase 3
Status	COMPLETED
Enrolment	20506
Start date	2002-10
Completion	2006-12

Conditions

Myocardial Infarction
Acute ST-Segment Elevation

Interventions

Enoxaparin sodium (XRP4563)

Primary outcomes

Composite of all-cause mortality and non-fatal myocardial re-infarction

Countries

United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Jordan, Latvia, Lebanon, Lithuania, Malaysia, Mexico